Apr 24, 2026 | Foundayo Trails Oral Wegovy 5-to-1 in Week 2; Inhibrx Draws $6.7B

Lilly's Foundayo logs just 3,707 prescriptions in week two vs. 18,410 for Novo's oral Wegovy — a 5:1 gap that sent Lilly stock tumbling. Inhibrx surges ~39% on Merck-led takeover interest at $53/share. EU backs Sanofi's tolebrutinib for MS despite FDA rejection. FDA issues psychedelics priority review vouchers.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Foundayo, orforglipron, Eli Lilly, Novo Nordisk, Wegovy, oral GLP-1, obesity, Inhibrx, INBRX-106, Merck, Merck KGaA, Ono Pharmaceutical, oncology, tolebrutinib, Cenrifki, Sanofi, multiple sclerosis, SPMS, Regeneron, Otarmeni, gene therapy, hearing loss, Compass Pathways, Usona Institute, Transcend Therapeutics, psychedelics, psilocybin, AbbVie, CRL, Novartis, Pluvicto, Kelonia Therapeutics, Intellia, CRISPR, Roche, Moderna, Daiichi Sankyo, Avalyn Pharma, Pfizer, Lilly